康惠製藥(603139.SH)完成收購山東友幫51%股權
格隆匯9月25日丨康惠製藥(603139.SH)公佈,2020年9月23日,公司召開第四屆董事會第七次會議,審議通過《關於收購山東友幫生化科技有限公司51%股權的議案》,並於當日簽署《陝西康惠製藥股份有限公司與來新勝關於山東友幫生化科技有限公司之股權轉讓協議》,以自有資金3,264萬元購買來新勝持有的山東友幫生化科技有限公司(以下簡稱“山東友幫”)51%股權。本次收購完成後,公司將持有山東友幫51%的股權,山東友幫成為公司的控股子公司,將納入公司合併財務報表範圍。
2020年9月24日,山東友幫已完成工商變更登記手續,並取得菏澤市定陶區行政審批服務局頒發的《營業執照》,現公司直接持有山東友幫51%權股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.